Joseph Hazelton

Joseph P. Hazelton is President and Chief Operating Officer of Dyadic International, where he leads corporate strategy, operations, and global commercialization of the company’s proprietary gene expression platforms for biologics and alternative proteins. He has been instrumental in scaling Dyadic’s scientific and commercial initiatives, advancing partnerships across biopharma, food, and industrial biotechnology sectors, and positioning the company for long-term growth. Mr. Hazelton brings over two decades of experience in life sciences, including leadership roles spanning commercial strategy, market access, and operations. Prior to Dyadic, he served as Chief Operating and Chief Commercial Officer at Charleston Laboratories, where he led global commercialization and portfolio strategy. Earlier in his career, he held multiple leadership roles at Novartis, driving managed markets strategy, payer engagement, and market access across major therapeutic areas. He is actively engaged in advancing next-generation biomanufacturing and enabling technologies that improve the cost, scalability, and accessibility of biologics. Mr. Hazelton holds a degree in English and Biology from the College of the Holy Cross.